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Purpose. Fentanyl is available as a transdermal system for the treatment of chronic pain in opioid-tolerant patients; however, it
carries a black box warningdue to both the potency ofthe product and the potential for abuse. In this report, we describe a case of
transbuccalandgastrointestinalingestionoffentanylpatches andthemanagementofsuchingestion.Summary.A32-year-oldman
wasbroughttotheemergencydepartment (ED)viaemergencymedicalservicesfortoxicingestionandsuicideattempt.Thepatient
chewed and ingested two illegally purchased transdermal fentanyl patches. In the ED, the patient was obtunded, dizzy and drowsy.
Initial vital signs showed the patient to be afebrile and normotensive with a heart rate of 63, respiratory rate of 16, and oxygen
saturation of 100% on 2 liters nasal cannula after administration of 2 milligrams of intravenous naloxone.The patient was treated
with whole bowel irrigation and continuous intravenous naloxone infusion for approximately 48 hours without complications.
Conclusion. Despite numerous case reports describing oral ingestion of fentanyl patches, information on the managementof such
intoxication is lacking. We report successful management of such a case utilizing whole bowel irrigation along with intravenous
push and continuous infusion naloxone.
1.Introduction
Fentanyl, a potent phenylpiperidine opioid agonist avail-
able as a transdermal patch, carries a black box warning
cautioning health care providers on both the potency of
the product and the potential for abuse and diversion
[1]. Numerous consumer Internet websites describe means
for abusing fentanyl patches, such as smoking, chewing,
freezing, or intravenous injection of the gel reservoir [2, 3].
In 2005, Goldberger and colleagues presented data from the
state of Florida which found fentanyl as the cause of 115
deaths [4]. Although anecdotal reports exist, there is little
published in medical literature regarding oral intoxication
of fentanyl patches [5–8]. We describe both the presentation
and management of a patient who ingested two fentanyl
patches.
2.Case Report
A 32-year-old white male was brought to the emergency
department (ED) via emergency medical services (EMS) for
a toxic ingestion. The patient was in a verbal altercation
around 0700 with his ex-wife, resulting her calling the police
department. Afterdiscovering lawenforcementwas enroute,
his ex-wife witnessed the patient chewing and ingesting two
illegally purchased 50 micrograms per hour transdermal
fentanyl patches, along with 6–8 milligrams of alprazolam.
EMS found the patient to be nonresponsive to verbal or
physical stimuli, bradycardic, and with miotic pupils. Two
milligrams of intravenous naloxone were administered by
EMS, which resulted in opioid reversal and arousal of the
patient. The patient was subsequently transferred to our
ED with ﬁndings of altered mental status, obtundation, and2 Case Reports in Medicine
drowsiness.Onarrival,lawenforcementcorroboratedtheex-
wife’s description of the patient ingesting the two fentanyl
patches and gave an account of the eventto the ED physician
and pharmacists. The patient admitted to regular use of
methamphetamine, opioids, and benzodiazepines and had
a past medical history bipolar disorder for which he took
no medications. His review of systems was negative, except
for the dizziness, drowsiness, and altered mental status,
and admission physical examination was unremarkable. The
patient’s initial set of vitals after 2 milligrams of intravenous
naloxone were as follows: afebrile, blood pressure 106/77,
heart rate 63, respiratory rate 16, and oxygen saturation
100% on 2 liters via nasal cannula. Initial chemistry,
liver function tests, and complete blood count were all
within normal limits. A urine drug screen was negative for
opioids,butpositiveforamphetaminesandbenzodiazepines.
Serum ethanol, acetaminophen, and salicylate levels were all
negative. A serum fentanyl level was not obtained.
The patient arrived in the ED at 0900. Upon arrival, the
patient was stabilized and assessed. At 1000, a naloxone drip
(8 micrograms per milliliter in 0.9% sodium chloride) was
initiated at 0.4 milligrams per hour and slowly titrated up
to 2 milligrams per hour due to returning signs of opioid
toxicity (bradycardia, respiratory rate <12, and declining
neurologic exam). Additionally, whole bowel irrigation with
polyethylene glycol 3350 via nasogastric tube was initiated
secondary to concerns for ingested patches creating a depot-
like eﬀect. The patient had one bowel movement in the
ED (no documentation that patches or remnants were
passed) and remained hemodynamically and neurologically
s t a b l eu n t i lt r a n s f e rt ot h em e d i c a li n t e n s i v ec a r eu n i ta t
approximately 2200 that evening. His naloxone drip was
titrated down to 0.2 milligrams per hour around 1200 of
his second hospital day and was eventually discontinued
that evening at 2300. He did not receive any additional
naloxone after this point. In total, he received approximately
15 milligrams of naloxone over these two days. He remained
cardiovascularly and neurologically stable throughout his
stayinthemedicalICU,wassubsequentlydowngradedtothe
medical ﬂoor on hospital day 3 (48 hours after admission),
and discharged from the hospital on day 4 at 1100.
3.Discussion
Multiple ingestions of fentanyl patches have been reported,
withoutcomesrangingfromtransient symptoms ofoverdose
(e.g., hypotension, altered mental status) to death. Van
Rijswijk and Van Guldener described the case of an 81-year-
old male with a history of multiple myeloma, osteoporosis,
and delirium who was found chewing on a fentanyl patch
[5].Hisnurse promptlyremoved thepatchfromthepatient’s
mouth; however, thirty minutes later, the patientbecame less
arousable and hypotensive. After administration of naloxone
0.4 milligrams and intravenous saline, the patient’s mental
status and blood pressure returned to baseline. Thomas
and colleagues published a case report of a 42-year-old
male with known drug abuse, including hospitalization for
drug overdose, who died subsequent to oral ingestion of
fentanyl patches [6]. Upon autopsy, the decedent had three
pieces of fentanyl patches in his stomach. Further history
reveals that the decedent commonly chewed, sucked on,
and swallowed fentanyl patches to obtain a high. Lastly,
Woodall and colleagues reported a case series of seven
deceased patients in whom oral administration of a fentanyl
patch was suspected to have contributed to their death [7].
Decedents ranged in age from 20 to 51 years and had oral
and transbuccal administration of a patch based on witness
reports or evidence of patch residue in the oral cavity.
Postmortem fentanyl serum concentrations ranged from 7
to 97ng/mL, whereas typical serum concentrations from
single dose studies with fentanyl transbuccal tablets (100–
800mcg) yield peak serum concentrations between 0.25
and 1.59ng/mL [9]. More recently, Carson and colleagues
presented a case of a 28-year-old white male who died in
the ED after chewing and aspirating a transdermal fentanyl
patch. On autopsy, the decedent had a beige foreign body
(later identiﬁed as the transdermal device) lodged in the
mainstem bronchus, and postmortem toxicological analysis
revealed a serum fentanyl level of 8.6ng/mL [8]. Fentanyl
serum levels are not performed in our facility’s laboratory,
and determining them would require sending them to an
outside laboratory. Due to the typical return time on these
types of labs, we felt an admission fentanyl level would be of
little beneﬁt to the medical team three days later.
Fentanyl is 50–65% bioavailable across the buccal mem-
brane when administered as a transbuccal system (e.g.,
lozenge and troche) [1, 9, 10]. However, when ingested
orally, fentanyl undergoes extensive ﬁrst-pass metabolism,
resulting in 20% escaping hepatic metabolism and entering
thesystemiccirculation.Therefore,asalludedtoinpublished
case reports, the time fentanyl stays in contact with the oral
mucosadirectly translates to the systemic absorption and the
severity ofthe overdose.Case reports describe eitherchewing
or suckingon the fentanyl patch, leading to extensive contact
time between the oral mucosa and the inner gel matrix.
Additionally, the reservoir of a fentanyl patch houses a large
dose of fentanyl. In the case of our patient, a 50 microgram
per hour patch stores 8400 micrograms of fentanyl [1]. If the
entire reservoir contents of one fentanyl patch were ingested,
approximately 1680 micrograms would enter the systemic
circulation. Assuming a 25% reduction for cross-tolerance,
this fentanyl dose is equivalent to 126 milligrams of intra-
venous morphine [11]. However, ingesting an intact patch
would not necessarily result in signiﬁcant gastrointestinal
absorption (i.e.,the drug would still remain within the intact
system). If the entire contents of one patch were removed
and administered transbuccally,t h i ss y s t e m i cl e v e lw o u l db e
approximatelythreetimes thatachievedwith gastrointestinal
absorption (i.e., approximately 5000 micrograms of fentanyl
or 375 milligrams of intravenous morphine). Thus, chewing
orsuckingonafentanylpatchincreases contacttimewiththe
buccal membrane and liberates drug from the transdermal
system, greatly increasing systemic absorption.
Our patient’s ED urine drug screen for opioids was
negative;however,thisdoesnotnecessarily excludeanopioid
ingestion. A urine drug screen’s ability to detect substances is
based on the assay, the drug (and metabolites, if applicable)Case Reports in Medicine 3
the screen is designed for, and a drug’s pharmacokinetics
[12]. To be detected in a urine drug screen, the substance
must be absorbed, metabolized, and then renally excreted.
In general, most standard urine screens for opioids detect
codeine, morphine, and metabolites of the two. Fentanyl is
a fully synthetic opiate that is structurally dissimilar from
morphine and codeine; therefore, the metabolites of fentanyl
are also dissimilar [12]. Fentanyl is primarily hepatically
metabolized, and the inactive metabolites (primarily nor-
fentanyl) are excreted in the urine. Only 10% of the parent
drug is excreted unchanged in the urine [11]. In order to
detect a fentanyl-related opioid intoxication, a urine drug
screen would need to assay exclusively for fentanyl or the
predominant metabolite norfentanyl.
The treatment approach in this patientwas twofold:limit
opioid toxicity and facilitate passage of the ingested patches.
Naloxone, a pure opioid antagonist at all opioid receptor
sites, has long been utilized in the ED and intensive care unit
for the treatment of opioid intoxication [11]. Whole bowel
irrigation using polyethylene glycol or a similar osmotic
laxative has been used successfully in the treatment of other
intoxications,suchaslithiumoringestionofextendedrelease
products [13, 14]. While activated charcoal is often a ﬁrst
choice for oral intoxications, we chose to utilize a diﬀerent
approach for two reasons. First, the eﬃcacy of single-dose-
activated charcoal decreases over time. In a 2005 position
paper, Chyka and Seger demonstrated decreased eﬃcacy
as the time from poisoning is increased from 30 minutes
postingestion to 180 minutes [15]. These authors questioned
the utility of charcoal use after one hour postingestion.
Secondly, drug must be available in the gastrointestinal
tract and must be bound by charcoal for this treatment
modality to be eﬀective [16]. Since the time from ingestion
to presentation to our ED was over 2 hours, the drug was,
at least partially, housed within the transdermal system, and
there are no data on adsorption of fentanyl to activated
charcoal, we opted away from this therapeutic option. Our
approach was to utilize a continuous infusion of naloxone
until the patient passed the patches in his stool and returned
to hisbaseline mental status. Unfortunately,the patches were
neverrecoveredinthepatient’sstoolandwerelaterpresumed
to have passed prior to transfer to the intensive care unit,
although it is possible that the patient extracted the fentanyl
from the patches and disposed them in a conventional
means prior to law enforcement and EMS arrival. Fentanyl
absorbed across the buccal membrane has an elimination
half-life of up to 12 hours; therefore, treating and monitoring
the patient for 72 hours would ensure, using the most
conservative estimate, 6 half-lives had passed and at least
98.5% of the drug had been eliminated [10].
Lastly, the patient coingested 6–8 milligrams of alpra-
zolam, perhaps leading to benzodiazepine overdose. While
a speciﬁc antidote for benzodiazepine ingestion exists (i.e.,
Flumazenil), we did not utilize it because of the unknown
duration of alprazolam (or other benzodiazepine) use.
Flumazenil may precipitate benzodiazepine withdrawal or
seizures, and routine administration of Flumazenil has been
questioned, leading some to recommend that the drug
rarely be utilized in benzodiazepine overdose [17, 18].
Additionally, despite an 11-hour half-life, the duration of
action of alprazolam is 5.1 ± 1.7 hours [11]. We, therefore,
adopted a more conservative approach when treating this
benzodiazepine ingestion by providing supportive care and
whole bowel irrigation.
4.Conclusions
Our case adds to the small body of literature which describes
oral ingestion of a fentanyl patch and is the only to describe
a treatment modality for this situation. Contact time with
the oral mucosa may be the most important factor in deter-
mining severityoforalfentanyl ingestion,as bioavailabilityis
signiﬁcantly higher via the buccal membrane.
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